2027 Benefits Planning Toolkit

As You Finalize Your 2027 Strategy

Explore the planning toolkit that helps benefits leaders evaluate GLP-1 strategy, manage long-term costs, and build a sustainable metabolic health strategy for 2027.
christina-wocintechchat-com-m-eF7HN40WbAQ-unsplash

The conversation has changed

It's no longer about whether to address metabolic disease like obesity and type 2 diabetes - it’s whether you’ve evaluated every option as you're finalizing your strategy.

Benefits leaders are now asking:

  1. Have we evaluated every option?
  2. Are we confident in this decision?
  3. What questions have we not asked?
  4. Can we justify this investment internally?
  5. Does this protect us against the risk we are actually carrying?
  6. Can our partner flex if/when our strategy changes?

Your 2027 Planning Toolkit

Everything you need as you finalize your 2027 plan

GLP-1 Strategy

Member Experience

Cost Strategy

Expert Perspectives

What we'd tell every benefits team as they finalize their strategy

Short clips on the questions that come up most in final stage evaluations.

How to build a sustainable approach to GLP-1s and member outcomes

00:39

Frank Dumont

Virta Executive Medical Director

How to build a sustainable approach to GLP-1s and member outcomes

Watch the video
How to modernize your GLP-1 approach

00:47

Laura Walmsley

Virta Chief Commerical Officer

How to modernize your GLP-1 approach

Watch the video
Considerations for dropping GLP-1 coverage

01:55

Frank Dumont

Virta Executive Medical Director

Considerations for dropping GLP-1 coverage

Watch the video

The questions we hear most

Virta's perspective on what benefit leaders need to know.

We already cover GLP-1s. How does Virta complement an existing GLP-1 strategy?

Coverage is not the same as a strategy. Without a plan for what happens after the prescription, spend compounds year over year with no defined endpoint. Virta pairs personalized nutrition with responsible prescribing so medication becomes a tool rather than a permanent line item. Members achieve weight loss on par with clinical drug trials, with or without a GLP-1.

Proof point: 13% average weight loss without Rx at one year1, against a 4.7% benchmark.

What happens when someone stops the medication?

This is the question most strategies do not answer. Weight regain after discontinuation is well documented in the drug trial literature. Virta has published peer-reviewed outcomes on sustained weight loss after GLP-1 deprescription.

Proof point: 85% of weight loss sustained one year after stopping a GLP-12, against a 28% benchmark.

How do we know this pays for itself?

Savings come from medication reduction, fewer complications, and lower utilization as health improves, and they are modeled with third-party validated methodology. Virta puts 100% of fees at risk in the first year for employer partners, so the financial case does not rest on projections alone.

Proof point: $301 to $6603 gross savings per participant per month depending on clinical complexity. Two-year ROI of 1.7:1 to 3.3:1 by program.

Will our people actually use it?

Engagement is where most point solutions quietly fail. Virta's enrollment and retention numbers are driven by a dedicated provider and coach model plus a communications program run by Virta.

Proof point: 30% enrollment and 83% retention at one year.4 5 to 10x increase in engagement among employers using Virta-led communications.5

Do we have to restrict GLP-1 access to make this work?
No. There are three clinical models, from medication access paired with nutrition, to a stepped nutrition-first progression. The model is selected to match whether the priority is member experience or cost savings, and it works alongside the existing PBM and Rx fulfillment strategy.
How does this fit with what we already have in place?
Virta contracts directly or through 54 health plan, PBM, and vendor partners, bills via claims or invoicing, and can go live in as little as 12 weeks. That means a 1/1 implementation is still achievable from a Q3 decision.

Why organizations choose Virta

85%

of weight loss sustained one year after GLP-1 deprescription

vs. 28% benchmark

$301-$660

gross savings per participant per month depending on clinical complexity

100%

fees at risk in the first year for employer partners

30%

average enrollment

5-10x increase in engagement with Virta-led communications

Still evaluating your options?

Talk with a Virta advisor about how metabolic health fits into your 2027 strategy.

Citations and Footnotes
  1. McKenzie AL, Athinarayanan SJ, et al. Nutrients, 2021 Feb 26;13(3):749
  2. McKenzie, A.L., Athinarayanan, S.J. Impact of Glucagon-Like Peptide 1 Agonist Deprescription in Type 2 Diabetes in a Real-World Setting: A Propensity Score Matched Cohort Study. Diabetes Ther (2024). https://doi.org/10.1007/s13300-024-01547-0
  3. Virta actuarial model (2027-trended) + Sept 2021 claims analysis, per program tier
  4. Hallberg SJ et al. Diabetes Ther. 2018;9(2):583-612 — cited directly in the Member Experience guide (83% retention in Virta Treatment vs. 90% in Standard Care)
  5. Virta book-of-business activation data among enterprise employer clients, stratified by communications strategy, data as of 6/20/2025